Enliven Total Current Assets from 2010 to 2025

ELVN Stock   21.35  0.45  2.06%   
Enliven Therapeutics Total Current Assets yearly trend continues to be very stable with very little volatility. Total Current Assets are likely to grow to about 321.4 M this year. Total Current Assets is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. View All Fundamentals
 
Total Current Assets  
First Reported
2019-12-31
Previous Quarter
318.1 M
Current Value
297 M
Quarterly Volatility
104.7 M
 
Covid
Check Enliven Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enliven Therapeutics' main balance sheet or income statement drivers, such as Other Operating Expenses of 100.9 M, Research Development of 78 M or Total Operating Expenses of 100.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.89. Enliven financial statements analysis is a perfect complement when working with Enliven Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Enliven Therapeutics Correlation against competitors.
To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.

Latest Enliven Therapeutics' Total Current Assets Growth Pattern

Below is the plot of the Total Current Assets of Enliven Therapeutics over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Enliven Therapeutics' Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enliven Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Current Assets10 Years Trend
Slightly volatile
   Total Current Assets   
       Timeline  

Enliven Total Current Assets Regression Statistics

Arithmetic Mean83,295,311
Geometric Mean31,252,147
Coefficient Of Variation136.52
Mean Deviation89,797,803
Median10,223,000
Standard Deviation113,716,225
Sample Variance12931.4T
Range313.7M
R-Value0.82
Mean Square Error4564.6T
R-Squared0.67
Significance0.0001
Slope19,558,802
Total Sum of Squares193970.7T

Enliven Total Current Assets History

2025321.4 M
2024306.1 M
2023266.2 M
202277.8 M
2021110.7 M
2020130.6 M
201930.6 M

About Enliven Therapeutics Financial Statements

Enliven Therapeutics investors utilize fundamental indicators, such as Total Current Assets, to predict how Enliven Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Current Assets306.1 M321.4 M
When determining whether Enliven Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enliven Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enliven Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enliven Therapeutics Stock:
Check out the analysis of Enliven Therapeutics Correlation against competitors.
To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.89)
Return On Assets
(0.21)
Return On Equity
(0.31)
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.